Skip to main content
Premium Trial:

Request an Annual Quote

Cobequid and Qiagen Sign Aquaculture Deals

Premium

TORONTO--Cobequid Life Sciences here and the Netherlands-based Qiagen announced an agreement to exploit the potential of DNA vaccines in aquaculture. Cobequid will gain nonexclusive access, limited to use for its aquaculture products, to specific components of Qiagen's proprietary DNA manufacturing technology targeted to gene therapy and genetic vaccination applications.

In a second deal, Cobequid will obtain from Qiagen worldwide exclusive rights under certain patents which cover the use of DNA vaccines in aquaculture to control viral and bacterial diseases and parasitic infections. Cobequid will take over an initial portfolio of five products related to the technologies that have been successfully laboratory tested.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.